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Abstract. Growing tumors develop additional new blood vessels to meet the demand for adequate
nutrients and oxygen, a process called angiogenesis. Cancer is a highly complex disease promoted by
excess angiogenesis; interfering with this process poses for an attractive approach for controlling tumor
growth. This hypothesis led to the identification of endogenous angiogenesis inhibitors generated from
type IV collagen, a major component of vascular basement membrane (VBM). Type IV collagen and the
angiogenesis inhibitors derived from it are involved in complex roles, than just the molecular construction
of basement membranes. Protease degradation of collagens in VBM occurs in various physiological and
pathological conditions and produces several peptides. Some of these peptides are occupied in the
regulation of functions conflicting from those of their original integral molecules. Tumstatin (α3(IV)NC1),
a proteolytic C-terminal non-collagenous (NC1) domain from type IV collagen α3 chain has been
highlighted recently because of its potential role in anti-angiogenesis, however its biological actions are
not limited to these processes. α3(IV)NC1 inhibits proliferation by promoting endothelial cell apoptosis
and suppresses diverse tumor angiogenesis, thus making it a potential candidate for future cancer therapy.
The present review surveys the physiological functions of type IV collagen and discovery of α3(IV)NC1 as
an antiangiogenic protein with a comprehensive overview of the knowledge gained by us towards
understanding its signaling mechanisms.
KEY WORDS: α3(IV)NC1; integrin receptors; non-collagenous domains from alpha 3 chain of type IV
collagen; signaling mechanisms; tumor angiogenesis; vascular basement membrane (VBM).
INTRODUCTION
The development of extracellular matrix (ECM), a
complex structure comprising different proteins, is a crucial
event in evolution of multicellular organisms. In addition to
providing mechanical support for cells, ECM also influences
cell behavior (1). ECM remodeling during physiological or
pathological processes generates new signals, particularly
between endothelial cells and basement membranes (BMs)
(2). BMs are thin layers of specialized ECM associated
closely with different cells (3). Different collagens together
with laminins, nidogens, heparan sulfate proteoglycans
(HSPG), fibulins, dystroglycan and other glycoproteins, are
major constituents of BM (4). Some of the non-collagenous
(NC1) C-terminal domains from different collagens were
identified to be antiangiogenic and anti-tumorigenic in
addition to their biological role in molecular architecture of
the BM (5,6).
During angiogenesis, new capillaries sprout from pre-
existing blood vessels by an invasive process “neovasculariza-
tion” that occurs in physiological (embryonic development,
reproduction and wound healing) and pathological (tumor
growth, metastasis, arthritis, age related macular degenera-
tion etc.) conditions (7). Early reports hypothesized that
tumor growth is strictly dependent on neovascularization, and
inhibition of vascular supply to growing tumors could
suppress tumor growth (7,8). Solid tumors cannot grow
beyond 2 to 3 mm in diameter without recruitment of their
own blood supply and nutrients, thus tumor growth depends
on balance between circulating endogenous pro-angiogenic
factors (VEGF, FGF, PDGF etc.) and endogenous angiogen-
esis inhibitors (antiangiogenic peptides generated from ECM
by proteases) (7,9). The ECM derived endogenous angio-
genesis inhibitors control three fundamental processes (tumor
cell proliferation, apoptosis, and tumor angiogenesis) that are
critical for growth of primary tumors and metastases (10).
Since these endogenously released circulating peptides play a
crucial role in anti-angiogenesis, much effort has been
focused on development and identification of endogenous
anti-angiogenic molecules from BM in the past decade aiming
to produce potential medical treatments. A search for
endogenous angiogenesis inhibitors led to the discovery of
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endostatin, a C-terminal NC1 domain from type XVIII
collagen α1 chain (5). To date several endogenous angiogen-
esis inhibitors were identified, some of them were cryptic
fragments released by proteolysis of ECM and the others are
of non-ECM origin (10). The angiogenesis inhibitors from
ECM includes a large multifunctional glycoproteins such as
thrombospondin, anastellin, a fibronectin fragment, fibulins
(COOH terminal fragments corresponding to fibulin 1D and
the domain 111 of fibulin 5), endorepellin, a COOH terminal
end of perlecan, (or perlecan domain V) (11–14). Some of the
type IV collagen derived NC1 domains posses characteristic
antiangiogenic activities that were first reported by Dr.
Brook’s group (6).
This review will illustrate a comprehensive overview of
type IV collagen, its physiological functions with specific
emphasis on the generation of α3 chain type IV collagen NC1
domain α3(IV)NC1 (tumstatin) an endogenous inhibitor of
angiogenesis. This review also highlights important features
of α3(IV)NC1 addressing signaling mechanisms in regulation
of tumor angiogenesis which would explain how this endog-
enous angiogenesis inhibitor regulates angiogenic balance in
the tumor bed.
PHYSIOLOGICAL FUNCTIONS OF TYPE IV
COLLAGEN
Type IV collagen is ubiquitously present in vascular
basement membrane (VBM) and is highly conserved among
vertebrates and invertebrates, regulating cell adhesion and
migration (15–17). Type IV collagen is one of the most
abundant constituents of basement membrane (BM) archi-
tecture that forms a network like structure in ECM (18,19).
Type IV collagen consists of six distinct gene products (α1 to
α6 chains) and their genomic localization shows a pair-wise
head-to-head arrangement with a bi-directional promoter,
that were mapped onto three different chromosomes (20–22).
Each α-chain in type IV collagen is composed of three distinct
domains, a cysteine-rich N-terminal 7S domain, a central long
triple helical domain and a globular C-terminal NC1 domain
(Fig. 1). The NC1 domains of type IV collagen are involved in
the assembly of α-chains to form heterotrimers and the 7S
domain is involved in the covalent assembly of heterotrimers
in a complex mesh like network that serves as a scaffold for
BM (18,19,23,24). Type IV collagen is found normally in the
BM, during certain pathological conditions associated with
tumor fibrosis, it accumulates in tumor interstitium (4).
α1(IV) and α2(IV) collagen chains are most abundant forms
of type IV collagen and are widely expressed and co-localized
in numerous tissue types, whereas α3–α6 chains show
temporal and spatial distribution, and expression in physio-
logical as well as pathological processes (25–29).
Several human genetic diseases provided insights into
the physiological role of type IV collagen. Mutations or
deletions in Col4α5, Col4α3 and Col4α4 chains are involved
in Alport syndrome (defective glomerular BM) and diffused
leiomyomatosis (a benign smooth muscle tumor) (30,31).
The C-terminal region of α3 chain of type IV collagen has
been identified as an autoantigen involved in Goodpasture
syndrome (an immune disease characterized by glomerulo-
nephritis and pulmonary hemorrhage) (29). Mouse models
for autosomal Alport syndrome have been developed and a
phenocopy of human disease was also reported (32).
GENERATION OF a3(IV)NC1 (TUMSTATIN)
FROM TYPE IV COLLAGEN
The proteolytic pathways involved in generation of NC1
fragments from type IV collagen are not well understood.
Several NC1 fragments were detected in the serum suggesting
that these fragments exist due to physiological cleavage of
ECM by proteases. Presumably, several distinct proteolytic
pathways are involved in generation of these NC1 domains;
however their generation is not extensively tested like as
endostatin, which is generated from type XVIII collagen α1
chain NC1 domain (33). To isolate NC1 domain from type IV
collagen, researchers isolated vascular basement membrane
(VBM) and extracted type IV collagen that was subjected to
different proteases. The different protease degradation frag-
ments in the supernatant were separated by gel filtration,
anion exchange chromatograph, HPLC etc. Several small
peptides were identified by amino acid sequence analysis and
immunoblotting using antibodies specific to type IV collagen
NC1 domains (34–37) (Fig. 2). Earlier we reported α3(IV)NC1
as a 28 kDa proteolytic NC1 peptide generated from α3
chain of type IV collagen by MMP-9 and MMP-2 (38,39).
Although we gained preliminary clues for in vitro processing of
type IV collagen NC1 domains, the exact mechanism of
generation of these NC1 domains still needs to be extensively
investigated.
BIOLOGICAL FUNCTIONS OF a3(IV)NC1
IN ANTI-ANGIOGENESIS
The biological functions of type IV collagen NC1
domains seem to be conserved throughout evolution. In
primitive invertebrate Hydra vulgaris, addition of NC1 type
(IV) collagen alters morphogenesis, blocking cell aggregation
and development (40). In vitro, NC1 type (IV) collagen
promotes axonal but not dendritic growth in rat embryos
sympathetic neurons, hexameric NC1 supports attachment
and migration of chicken neural crest cells, but not intact
dimers (41,42). These results confirm that the biological
functions of NC1 domains are conformation dependent.
Proteolytic degradation of type IV collagen may induce
exposure of cryptic sites which involved in binding of
integrins, and sends new signals between cells and basement
membrane (43). Cells bind to type IV collagen, and this
binding was inhibited by type IV collagen derived peptides
was demonstrated in several cell types that was first reported
Fig. 1. A hypothetical structure of α3 chain type IV collagen. Linear
structure of human α3 chain type IV collagen composed of three
distinct domains: a cysteine rich N-terminal 7S domain, a central
triple helical domain with multiple small interruptions and a globular
C-terminal non-collagenous (NC1) domain.
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in 1986 (44,45). A synthetic peptide encompassing residues
183–205 of α3 chain type IV collagen NC1 domain was shown
to specifically inhibit activation of polymorphonuclear leuko-
cytes (46). This peptide binds to an integrin complex,
promotes adhesion, chemotaxis and inhibits proliferation of
various human cancer cell lines (47,48). In addition a peptide
derived from α3(IV)NC1 was shown to prevent glomerular
hypertrophy in the early stages of diabetic nephropathy (49).
Direct interaction between α3(IV)NC1 domain and β3
integrin signaling inhibited focal adhesion kinase (FAK) and
phosphorylation of phosphatidylinositol 3-kinase (PI-3K)
(50). Furthermore, inhibition of cell migration was reported
in melanoma and fibrosarcoma cells using native type IV
collagen or 185–205 peptide, with a decrease in expression of
membrane-bound metalloproteinase (MT1-MMP) and β3
integrin subunit with a decrease in the levels of activated
membrane-bound matrix metalloproteinase-2 (MMP-2)
(51). MMP-2 is involved in tumor progression and metastasis
and its activation is dependent on MT1-MMP/TIMP-2
(tissue inhibitor of metaloproteinase-2) complexes (52,53).
α3(IV)NC1 inhibited expression of MT1-MMP in bronchial
tumor cell line and 185–205 peptide inhibited their invasion
on [α1(IV)]2 α2(IV) collagen (54). Altogether, this data
indicates the ability of this peptide to inhibit proliferation
and regulates cellular adhesion and motility. The α3 type IV
collagen chain has specific interaction with invasive cancer
cells. In the context of tumor progression and metastasis, the
presence of α3(IV)NC1 may negatively regulate the invasion
process. Interestingly, in lungs, where α1, α2, α3, α4 and
α5(IV) collagen chains are expressed in normal alveolar BM,
development of bronchoalveolar carcinoma correlates with
loss of α3, α4 and α5 chain expression and an increase in α1
and 2 chain expression (55). The heterotrimer [α1(IV)]2 α2 is
permissive for the invasion of different cancer cell lines and
mediates pro-MMP-2 activation (56).
Synthesis of type IV collagen by VBM is a prerequisite for
angiogenesis (57,58). Several groups have focused their
attention on potential anti-angiogenic properties of NC1
domains. Dr. Brook’s group first generated all six type IV
collagen NC1 domains and described the antiangiogenic effects
of α2, α3 and α6(IV)NC1 by chorioallantoic membrane
(CAM) assays (6). Later several researchers including myself
re-conformed anti-angiogenic activities of these domains and
nomenclatured as α1(IV)NC1 (arresten), α2(IV)NC1 (cansta-
tin) and α3(IV)NC1 (tumstatin) (50,59–65). These type IV
collagen derived NC1 domains inhibit endothelial cell prolifer-
ation and migration (38,50,59–62). α3(IV)NC1 seems to be
studied more extensively compared to other domains of type
IV collagen. Interestingly, none of the whole NC1 domains
inhibited proliferation of cancer cell lines, as observed with the
185–205 (α3(IV)NC1) peptide, indicating that this effect is
dependent on partial degradation of the NC1 domain.
Fig. 2. Generation of antiangiogenic cryptic domains from VBM. Vascular basement membrane was extracted to isolate type IV collagen. The
assembled types IV collagen (monomer or trimer) has no antiangiogenic activity. Interestingly when type IV collagen was digested with matrix
metalloproteinases (MMP-2/-9), antiangiogenic fragments were identified. Four out of six non-collagenous (NC1) domains of type IV collagen
were discovered as antiangiogenic (α1, α2, α3 and α6(IV)NC1) whereas α4 and α5(IV)NC1 were not reported to be showing similar functions.
The lengths of NC1 domain are approximately 231 amino acids shown in the structure. α3(IV)NC1 (tumstatin) a 28 kDa protein was cloned in
baculovirus expression system and identified that it binds to cell surface integrins to mediate its antiangiogenic activity (66,100,101).
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INHIBITION OF ANGIOGENESIS BY a3(IV)NC1
α3(IV)NC1 inhibits formation of tubular structures in
mouse aortic endothelial cells embedded in Matrigel and
block the recruitment of capillaries in Matrigel plugs and
inhibits growth of different tumors in mouse models (6, 38,
62, 63, 66). But what are the cell surface integrin receptor(s)
involved in these antiangiogenic actions of α3(IV)NC1? It is
clear that different integrins are key targets of α3(IV)NC1.
α3(IV)NC1 binds to αVβ3 integrin in an RGD-dependent
and independent manner (67). Integrin αVβ3 interacts with
α3(IV)NC1 through two distinct regions, comprising residues
54–132 and 185–203 amino acids. The first site is involved in
the anti-angiogenic activity, whereas the second site is
involved in anti-proliferative activity on cancer cell lines
(68). Adhesion of endothelial cells to α3(IV)NC1 also seem
to occur through α6β1 and αVβ5 integrins, but the signifi-
cance of these integrins interaction is not yet clear (63, 67). It
is also known that type IV collagen NC1 domain, interacts
with cells via α1β1 and α2β1 integrins (69). During angio-
genesis cryptic integrin-binding sites in type IV collagen are
exposed that induce a switch in integrin recognition, with a
loss of α1β1 binding site and a gain of αVβ3 binding site that
might be due to denaturation and concomitant degradation of
type IV collagen by MMPs (70,71). These results indicate
that α3(IV)NC1-integrin interactions are involved in the
regulation of angiogenesis.
A peptide composed of residues 45–132 of α3(IV)NC1
fragment is sufficient to inhibit in vitro and in vivo angiogen-
esis by increasing apoptosis in endothelial cells (72). These
results confirm specific regulatory sub-domains in α3(IV)NC1
controlling adhesion, proliferation or apoptosis in various cell
types. The functional specificity of these sub domains from
α3(IV)NC1 in endothelial or cancer cells is very interesting.
Indeed, the recently published 3D crystal structure of type IV
collagen NC1 domain reveals N and C homologous sub
domains. The major difference between these sub-domains
for each chain is in the region from residues 86–95 in the N
sub-domain and 196–209 in the C sub-domain. These regions
overlap two sequences that were previously identified to be
having anti-angiogenic and anti-proliferative effects in cancer
cells (73). α3(IV)NC1 or its peptides interaction with
integrins seems to be involved in the disruption of contacts
between endothelial or tumor cells and the BM, leading to
apoptosis in these cells.
aVb3/a3b1 INTEGRIN MEDIATED SIGNALING
REGULATED BY a3(IV)NCI
The signaling mechanism involved in inhibition of
endothelial cell-specific protein synthesis by α3(IV)NC1 by
binding to αVβ3 integrin was reported by us (65). In addition
soluble α3(IV)NC1 induces endothelial cell apoptosis by
interacting with αVβ3 integrins and inhibits adhesion to
VEGF in the matrix, and this effect was potentiated by anti-
αVβ3 blocking antibody. Immobilized VEGF almost abol-
ished endothelial cell apoptosis through interactions with
these integrins. The inhibition of αVβ3 engagement with
immobilized VEGF by α3(IV)NC1, inhibited most of its
survival activity (74) (Fig. 3). These mechanisms have since
been implicated in inhibition of tumor growth from several
tumor cell lines such as renal cell carcinoma (786-O), CT26
(colon adenocarcinoma), prostate carcinoma (PC3), Lewis
lung carcinoma (LLC), human lung cancer (H1299), human
prostate cancer (DU145), human fibrosarcoma (HT1080) and
teratocarcinoma (SCC-PSA1) by inhibiting tumor angiogen-
Fig. 3. Schematic illustration of apoptotic effects of α3(IV)NC1 in endothelial cell. a Proliferating endothelial cells binds to extra cellular
matrix (ECM), bound VEGF or to immobilized VEGF by integrins leading to cell survival, whereas floating cells will die. b When integrin
αVβ3 is engaged with ECM bound VEGF, α3(IV)NC1 can induce endothelial cell apoptosis. c Whereas the interaction between ECM-bound
VEGF and integrin αVβ3 when blocked by anti-αVβ3 integrin antibody, α3(IV)NC1 induced apoptosis is significantly enhanced.
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esis (6,63,66,67,75). The antiangiogenic activity of α3(IV)NC1
was conferred by its interaction with integrin αVβ3 and
inhibiting activation of focal adhesion kinase (FAK), PI-3K,
Akt/protein kinase B, mammalian target of rapamycin
(mTOR) and prevents dissociation of eukaryotic translation
initiation factor 4E (eIF4E) from 4E binding protein (4E-
BP1) leading to the inhibition of Cap-dependent translation
specifically in proliferating endothelial cells (65,76). Further-
more, these findings indicate a specific role for integrins in
mediating cell specific inhibition of protein translation
suggesting a potential specific mechanism of α3(IV)NC1 on
endothelial cells.
The antiangiogenic activity of α3(IV)NC1 is localized
on two distinct integrin binding regions on the molecule that
is separate from the region responsible for the anti-tumor
cell activity (62,63). αVβ3 integrin binds to the NH2-terminal
end comprising amino acid residues 54–132 region of
the α3(IV)NC1 that is presumably associated with Cap-
dependent translation inhibition and antiangiogenic activity
(65). Whereas α3β1 integrin binds to C-terminal region
185–203 residues associated with antitumor activity (66,77).
These data correlate with earlier observations that α3(IV)NC1
binds to α3β1 integrin and transdominantly inhibits expression
of αVβ3 integrin (73). Several previous studies have investi-
gated the role of α3(IV)NC1 and its peptides in tumor growth
suppression due is to direct pro-apoptotic effects on endothe-
lial cells (72,78,79). Interestingly recent studies clearly show
that in addition to tumor suppressive action of α3(IV)NC1
or its peptide (T3; C-terminal end comprising amino acid
residues 133–244 region of the α3(IV)NC1) directly inhibits
growth of glioma cells (80). In addition a cyclopeptide derived
from α3(IV)NC1 (YSNSG) was also shown to inhibit human
melanoma cell proliferation about 45% (81). These results
indicates that α3(IV)NC1 affects endothelial and non-
endothelial cells, and does not appears to be specific for
endothelial cells.
Surprisingly, abnormal tumorigenesis is observed in mice
lacking α3(IV)NC1, the secret behind this abnormal tumor
growth needs to be investigated. No significant tumor angio-
genesis effect was observed in mice lacking collagen XVIII
indicating that α3(IV)NC1 is playing a role in pathological
angiogenesis to decrease tumor progression (38,82–85). How-
ever, in a controlled angiogenic process such as wound healing,
α3(IV)NC1 does not affect the overall neovascularization (38).
Although α3(IV)NC1 is efficient in reducing tumor neo-
vascularization, its exact role needs to be deciphered.
Recently we identified that α3(IV)NC1 inhibits hypoxia
induced cyclo-oxygenase-2 (COX-2) expression in endothelial
cells via FAK/Akt/NFκB (nuclear transcription factor-kappa
B) pathways, leading to decreased tumor angiogenesis and
tumor growth in an α3β1 integrin dependent manner (66).
Hypoxic COX-2 expression was inhibited in β3 integrin null
endothelial cells upon treatment with α3(IV)NC1, indicating
that COX-2 mediated signaling is not regulated through
αVβ3 integrin (66). Interestingly COX-2 expression was also
not affected when hypoxic α3 integrin null endothelial cells
were treated with α3(IV)NC1 protein, confirming that COX-
2 expression was regulated by α3β1 integrin (66). In addition
to COX-2 inhibition, the down stream VEGF and bFGF
protein expression was also inhibited upon α3(IV)NC1
treatment to endothelial cells (66).
COX-2 is induced by a variety of factors, including
cytokines, growth factors, and tumor promoters (86). Hypox-
ia induced COX-2 expression regulated by NFκB (87). There
is ample evidence that COX-2 over expression contributes to
carcinogenesis and its disruption can both prevent and treat a
variety of solid tumors (88,89). COX-2 was also reported to
play a key role in tumor angiogenesis (90). Moreover, several
investigators have demonstrated that blockade of COX-2
mediated pathway serves as a therapeutic benefit in different
cancer models and potential target for tumor angiogenesis
(91,92). These findings indicate that there may be several
targets for the inhibitory effects of α3(IV)NC1 in tumor-
angiogenesis, including or in addition to COX-2, VEGF and
bFGF (66). The above studies supports the antiangiogenic
and anti-tumorigenic activity of α3(IV)NC1 mediated
through αVβ3 and α3β1 integrins (Fig. 4). Integrin α3β1
mediates signaling events that influence downstream effects
of COX-2 expression that is central to the mechanism of
α3(IV)NC1 regulating tumor-angiogenesis (66).
Fig. 4. Schematic illustration of distinct molecular signaling pathways
mediated by α3(IV)NC1. α3(IV)NC1 binds to different cell surface
integrins, when it binds to αVβ3 integrin in endothelial cells it inhibits
phosphorylation of FAK. Inhibition of FAK activation leads to
inhibition of FAK/PI-3K/Akt/mTOR/eIF4E/4E-BP1 cap dependent
translation resulting in activation of apoptosis and cell death. When
α3(IV)NC1 binds to α3β1 integrin transdominantly inhibits αVβ3
expression in cells and inhibits NFκB mediated signaling in hypoxic
conditions leading to inhibition of COX-2/VEGF/bFGF expression,
resulting in inhibition of hypoxic tumor angiogenesis.
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Three possible conclusions can be drawn from the
signaling mechanisms of α3(IV)NC1 in regulating hypoxic
tumor-angiogenesis in addition to Cap-dependent translation
in endothelial cells. α3(IV)NC1 binds to cell surface integrins
and inhibits hypoxia induced tumor angiogenesis by (1)
inhibiting NFκB activation, leading to inhibition of COX-2
expression, which in turn results in (2) down regulation of
hypoxia induced VEGF/bFGF expression in addition to
inhibition of cap dependent translation (Table I). (3) In addi-
tion, α3(IV)NC1 possibly by binding to its several receptors,
crosstalk with other cell surface receptors such as VEGF and
bFGF, and activate specific caspase mediated signaling and
regulate cell functions, as similarly shown by another type IV
collagen NC1 domain, α2(IV)NC1 (93). The decrease in COX-
2 expression under hypoxia results in decreased VEGF/bFGF
expression representing one of the primary molecular mecha-
nisms by which α3(IV)NC1 inhibits pathological angiogenesis
that is essential for the growth of tumors (66).
Besides αVβ3 and α3β1 integrins, another common target
for α3(IV)NC1 seems to be inhibition of MMP-2 activation. A
direct interaction with the catalytic domain has been shown in
case of endostatin, such an interaction has not been demon-
strated for α3(IV)NC1, and needs further investigation in this
direction. An increase in the basal level of pro-MMP-2 activity
was also observed in α3(IV)NC1 null mice (94). Similar
possible interaction with other MMPs might exist in the
generation of α3(IV)NC1 and warrants further investigation.
CONCLUSIONS AND PERSPECTIVES
In the last decade several different endogenous angio-
genesis inhibitors have been discovered from ECM.
Researchers identified that these endogenous angiogenesis
inhibitors, through pharmacological studies, showed promising
anti-tumor activity, but their mechanism of action and
physiological role is not yet understood. Type IV collagen
derived endogenous angiogenesis inhibitor, α3(IV)NC1, binds
to different cell surface integrins and exerts its effects through
multiple mechanisms including induction of endothelial cell
apoptosis, inhibition of cell proliferation, tube formation in
endothelial cells, and inhibit or alter the functions of pro-
angiogenic growth factors. In this regard α3(IV)NC1 demon-
strates a genetic evidence for its physiological function in
negative regulation of tumor growth and progression in
mice (66,73). However, the detailed physiological and
biological functions of α3(IV)NC1 are not yet completely
identified. The anti-angiogenic and anti-tumorigenic activi-
ties of α3(IV)NC1 is dependent on αVβ3 and α3β1
integrins (66,73). In mice deletion of β3 integrin or deletion
of α3(IV)NC1 enhanced tumor angiogenesis, suggesting a role
for this integrin and this NC1 domain in limiting angiogenesis
in vivo (38,95) The anti-angiogenic activities of α3(IV)NC1 is
partly dependent on binding to αVβ3 integrin which also
supports this hypothesis. Whereas anti-tumorigenic activities of
α3(IV)NC1 are dependent on its binding to α3β1 integrin
which transdominantly inhibits αVβ3 integrin (73). Another
feature of α3(IV)NC1 is inhibition of various signaling
molecules which are involved in cell survival. However anti-
angiogenic and anti-tumorigenic activities of α3(IV)NC1 also
seems to be because of the inhibition of different locally
released growth factors (66).
In addition several angiogenic inhibitors including αV
integrin antagonist EMD 121974, 2-methoxyestradiol (pan-
zam) and MMP-2, -9 inhibitor COL-3 etc. are currently in one
of two phases in human clinical trails (96). A recent study
suggests that up-regulation of specific pro-angiogenic factors
is a common mechanism for colorectal and renal carcinoma
cells to evade inhibition by several of extracellular derived
endogenous angiogenesis inhibitors (97). Questions regarding
resistance to these angiogenesis inhibitors do remain unan-
swered; however a combination of radiation therapy with
other anti-angiogenic therapies may also prove to be clinically
useful and effective (97). Earlier lessons from preclinical trials
of angiostatin, endostatin, thrombospondin-1 (ABT-510) and
2-ME suggest that more basic research is required for better
understanding of the mechanisms of action associated with
each of these endogenous angiogenesis inhibitor molecules.
Presently, some of the anti-angiogenic agents such as
Bevacizumab and several other VEGFR tyrosine kinase
inhibitors; vatalanib (PTK787/ZK 222584), semaxanib
(SU5416), sunitinib (SU11248), sorafenib (BAY 43-9006)
etc., are in clinical trials (98,99). Further extensive evaluation
of α3(IV)NC1 through pharmacokinetic studies is needed to
address this molecule as an inhibitor of angiogenesis and to
be considered for the clinical trials in the context of tumor
angiogenesis and cancer.
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Table I. Signaling Mechanisms Mediated by Angiogenesis Inhibitor
α3(IV)NC1
Angiogenesis inhibitor name Human α3(IV)NC1 (tumstatin)
α3(IV)NC1 origin α3 chain type IV collagen
non-collagenous domain
Generation of α3(IV)NC1 From ECM by MMP-9, -2 and ??
α3(IV)NC1 binding integrins CD47/IAP, αVβ3, α6β1,
αVβ5, α3β1
Endothelial proliferation Effects by α3(IV)NC1
Endothelial migration Insignificant effect by α3(IV)NC1
Endothelial tube formation Effects by α3(IV)NC1
Endothelial cells apoptosis By caspases-3 activation,





BP1 and NFκB/COX-2 mediated
signaling
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